Global Wilms Tumor Pipeline Insight Report 2019 - ResearchAndMarkets.com

DUBLIN--()--The "Wilms Tumor - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

A detailed picture of the Wilms Tumor pipeline landscape is provided which includes the disease overview and Wilms Tumor treatment guidelines.

The assessment part of the report embraces, in depth Wilms Tumor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Wilms Tumor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Wilms Tumor Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Wilms Tumor targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Wilms tumor pipeline report covers 1 company. Some of the key players include Oasmia Pharmaceutical (Doxorubicin).

Scope of the report

  • The Wilms Tumor report provides an overview of therapeutic pipeline activity for Wilms Tumor across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Wilms Tumor therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
  • Detailed Wilms Tumor Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Wilms Tumor

Key Topics Covered:

1. Report Introduction

2. Wilms Tumor (Nephroblastoma)

2.1. Wilms Tumor Disease Overview

2.2. Wilms Tumor History

2.3. Wilms Tumor Symptoms

2.4. Wilms Tumor Causes

2.5. Wilms Tumor Pathophysiology

2.6. Wilms Tumor Diagnosis

2.6.1. Diagnostic Guidelines

3. Wilms Tumor Current Treatment Patterns

3.1. Treatment Guidelines

4. Wilms Tumor - An Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Wilms Tumor companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Wilms Tumor Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing/Partnering) Analysis

4.1.2.2. Wilms Tumor Acquisition Analysis

4.2. Clinical Assessment of Pipeline Drugs

4.2.1. Assessment by Phase of Development

4.2.2. Assessment by Product Type (Mono/Combination)

4.2.2.1. Assessment by Stage and Product Type

4.2.3. Assessment by Route of Administration

4.2.4. Assessment by Molecule Type

4.2.5. Assessment by MOA

5. Wilms Tumor Pipeline Therapeutics

5.1. Late Stage Products (Phase-III)

5.1.1. Comparative Analysis

5.2. Mid Stage Products (Phase-II)

5.3. Early Stage Products (Phase-I)

5.4. Pre-clinical and Discovery Stage Products

5.5. Inactive Products

6. Wilms Tumor -Products Analysis

6.1. Product Profiles

6.1.1. Doxorubicin- Oasmia Pharmaceutical

6.1.1.1. Product Description

6.1.1.1.1. Product Overview

6.1.1.1.2. Mechanism of Action

6.1.1.2. Research and Development

6.1.1.2.1. Clinical Studies

6.1.1.2.1.1. Detailed Study Description

6.1.1.2.1.2. Study Results

6.1.1.2.1.3. Clinical Trials: Tabular View

6.1.1.3. Product Development Activities

6.1.1.3.1. Tabulated Product Summary

6.1.1.3.1.1. General Description Table

7. Recent Technologies

8. Wilms Tumor Key Companies

8.1. Oasmia Pharmaceutical

9. Wilms Tumor Key Products

9.1. Doxorubicin

10. Dormant and Discontinued Products

10.1. Dormant Products

10.1.1. Reasons for being dormant

10.2. Discontinued Products

10.2.1. Reasons for the discontinuation

11. Wilms Tumor - Unmet Needs

12. Wilms Tumor - Future Perspectives

13. Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/to1b6

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900